Low BAR allows IPF patients to live longer

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal and age-related interstitial lung disease whose etiology and pathogenesis are still largely unknown. It is important to identify IPF patients at high risk of mortality so that early appropriate treatment can improve their prognosis. Therefore, the investigation of available and reliable prognostic biomarkers for IPF is crucial.